Bexotegrast (PLN-74809)
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.
View full company profileAbout Pliant Therapeutics
Pliant Therapeutics is a clinical-stage biotech focused on discovering and developing breakthrough therapies for fibrotic diseases, a class of serious conditions with high unmet medical need. The company's scientific foundation is built on targeting tissue-specific integrins to inhibit TGF-β activation, aiming for a superior therapeutic profile compared to broad TGF-β inhibitors. Its lead asset, bexotegrast, has demonstrated promising Phase 2a data in IPF and PSC, positioning the company to potentially address multi-billion dollar markets. Pliant's strategy leverages a proprietary integrin platform to build a pipeline of oral therapies for fibrosis across multiple organs.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |